Edition:
United States

Teijin Ltd (3401.T)

3401.T on Tokyo Stock Exchange

2,010JPY
19 Oct 2018
Change (% chg)

¥-20 (-0.99%)
Prev Close
¥2,030
Open
¥2,010
Day's High
¥2,013
Day's Low
¥1,992
Volume
1,210,600
Avg. Vol
1,076,550
52-wk High
¥2,603
52-wk Low
¥1,954

Latest Key Developments (Source: Significant Developments)

Teijin lowers conversion price for 2018 due and 2021 due euro-yen denominated convertible bonds
Tuesday, 8 May 2018 10:51pm EDT 

May 9(Reuters) - Teijin Ltd <3401.T>:Says it lowers the conversion price for 2018 due euro-yen denominated convertible bonds to 1,998.6 yen per share, from 2,026.0 yen per share.Says it lowers the conversion price for 2021 due euro-yen denominated convertible bonds to 1,964.7 yen per share, from 1,991.7 yen per share.Effective April 1.  Full Article

Infocom to acquire 9.8 pct stake in Papyless
Wednesday, 28 Mar 2018 05:10am EDT 

March 28 (Reuters) - Infocom Corp <4348.T>:Says it will acquire 9.8 percent stake (969,500 shares) in Papyless Co Ltd <<<3641.T>>> on March 29 .  Full Article

Teijin to merge with fiber unit
Thursday, 30 Nov 2017 03:53am EST 

Nov 30(Reuters) - Teijin Ltd <3401.T>:Says it will merge with a Tokyo-based fiber consolidated subsidiary.Merger effective April 1, 2018.Says the subsidiary will be dissolved after the merger .  Full Article

R&I affirms Teijin's rating at "A-" and says stable outlook -R&I
Thursday, 16 Nov 2017 01:34am EST 

Nov 16 (Reuters) - Teijin Ltd <3401.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I.Says rating outlook stable -R&I.  Full Article

Teijin lowers conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds
Thursday, 2 Nov 2017 03:12am EDT 

Nov 2 (Reuters) - Teijin Ltd <3401.T>:Says it lowered the conversion price for 2018 due euro-yen denominated convertible bonds to 2,026 yen per share, from 2,035.7 yen per share, after Oct. 1 .Says it lowered the conversion price for 2021 due euro-yen denominated convertible bonds to 1,991.7 yen per share, from 2,001.3 yen per share, after Oct. 1 .  Full Article

Merz, Teijin announce partnership to bring Xeomin to Japan
Thursday, 12 Oct 2017 06:56am EDT 

Oct 12 (Reuters) - Teijin Ltd <3401.T>::Merz and Teijin announce partnership to bring Xeomin (Incobotulinumtoxina) to Japan.Entered into strategic license and co-development agreement with merz for commercialization of xeomin (incobotulinumtoxina) for Japan​.Merz sponsors 2 clinical trials in Japan covering spasticity of upper, lower limbs; upper limb trial completion seen in 2018​​.‍Under terms of agreement, Merz will receive an upfront payment in addition to milestones and royalties​.  Full Article

Teijin says co-sale of equity interests in film business joint ventures
Tuesday, 10 Oct 2017 09:37pm EDT 

Oct 11 (Reuters) - Teijin Ltd <3401.T>:* Says it will jointly sell all of the.  Full Article

Teijin to transfer rights and obligations to unit TEIJIN FRONTIER
Monday, 31 Jul 2017 03:50am EDT 

July 31(Reuters) - Teijin Ltd <3401.T>:Says it will transfer rights and obligations, including inventories, investment securities and capital invested into group company, to wholly owned unit TEIJIN FRONTIER CO., LTD..Effective Oct. 1.  Full Article

JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin
Tuesday, 18 Jul 2017 03:15am EDT 

July 18(Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it entered into co-development and license agreement with Teijin Ltd <<<3401.T>>>, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18.  Full Article

Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan
Thursday, 13 Jul 2017 07:40am EDT 

July 13 (Reuters) - Radius Health Inc ;:Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan.Radius Health Inc - ‍radius to receive upfront and milestone payments, royalties, and an option for co-promotion​.Radius Health - ‍Teijin granted a right of reference to Radius regulatory data.Radius Health - co maintains full global rights to its development program for Abaloparatide-Transdermal which is not part of agreement with Teijin.Radius Health - ‍Teijin also granted use of Radius intellectual property for development, manufacture and commercialization of abaloparatide-sc for Japan​.Radius Health Inc - ‍collaboration agreement provides Teijin with right to manufacture abaloparatide-sc for commercial supply in Japan​.Radius Health-‍Teijin conducting, funding Japanese phase 3 development program; parties may further collaborate in future in new indications for product​.  Full Article